Kelun-Biotech (SKB BIO-B) Secures HKEX Nod for Full H-Share Circulation, Converting 8.21 Million Shares

Bulletin Express

04/08

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (SKB BIO-B) has received Hong Kong Stock Exchange approval to convert and list 8.21 million domestic and unlisted foreign shares as H shares under its Full Circulation programme, the company disclosed on 8 April 2026.

The newly converted shares represent 3.52% of Kelun-Biotech’s total share capital. Upon completion, the proportion of H shares in issue will rise from 69.80% to 73.32%, while domestic shares will fall from 28.21% to 26.68%. All unlisted foreign shares (previously 1.99% of capital) will be eliminated.

Kelun-Biotech will now proceed with the remaining conversion and trading formalities and will update the market on further progress. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1161871922"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1161871922\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1161871922?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-08 21:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161871922","market":"hk","top_or_hot":-1,"title":"Kelun-Biotech (SKB BIO-B) Secures HKEX Nod for Full H-Share Circulation, Converting 8.21 Million Shares","media":"Bulletin Express","content":"<p>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (SKB BIO-B) has received Hong Kong Stock Exchange approval to convert and list 8.21 million domestic and unlisted foreign shares as H shares under its Full Circulation programme, the company disclosed on 8 April 2026.</p>\n<p>The newly converted shares represent 3.52% of Kelun-Biotech’s total share capital. Upon completion, the proportion of H shares in issue will rise from 69.80% to 73.32%, while domestic shares will fall from 28.21% to 26.68%. All unlisted foreign shares (previously 1.99% of capital) will be eliminated.</p>\n<p>Kelun-Biotech will now proceed with the remaining conversion and trading formalities and will update the market on further progress. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kelun-Biotech (SKB BIO-B) Secures HKEX Nod for Full H-Share Circulation, Converting 8.21 Million Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKelun-Biotech (SKB BIO-B) Secures HKEX Nod for Full H-Share Circulation, Converting 8.21 Million Shares\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-04-08 21:21</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (SKB BIO-B) has received Hong Kong Stock Exchange approval to convert and list 8.21 million domestic and unlisted foreign shares as H shares under its Full Circulation programme, the company disclosed on 8 April 2026.</p>\n<p>The newly converted shares represent 3.52% of Kelun-Biotech’s total share capital. Upon completion, the proportion of H shares in issue will rise from 69.80% to 73.32%, while domestic shares will fall from 28.21% to 26.68%. All unlisted foreign shares (previously 1.99% of capital) will be eliminated.</p>\n<p>Kelun-Biotech will now proceed with the remaining conversion and trading formalities and will update the market on further progress. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06990","symbol_name":"科倫博泰生物","start_time":0,"source_url":"","article_id":"1161871922","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161871922","pubTimestamp":1775654495,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (SKB BIO-B) has received Hong Kong Stock Exchange approval to convert and list 8.21 million domestic and unlisted foreign shares as H shares under...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06990":"科伦博泰生物"},"translate_title":"科伦生物（SKB BIO-B）获得港交所批准H股全流通，转换821万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":1},"content_text":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (SKB BIO-B) has received Hong Kong Stock Exchange approval to convert and list 8.21 million domestic and unlisted foreign shares as H shares under its Full Circulation programme, the company disclosed on 8 April 2026.\nThe newly converted shares represent 3.52% of Kelun-Biotech’s total share capital. Upon completion, the proportion of H shares in issue will rise from 69.80% to 73.32%, while domestic shares will fall from 28.21% to 26.68%. All unlisted foreign shares (previously 1.99% of capital) will be eliminated.\nKelun-Biotech will now proceed with the remaining conversion and trading formalities and will update the market on further progress. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}